These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 19698585)

  • 1. A review of the efficacy and tolerability of venlafaxine.
    Dierick M
    Eur Psychiatry; 1997; 12 Suppl 4():307s-13s. PubMed ID: 19698585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonin and Norepinephrine Reuptake Inhibitors.
    Shelton RC
    Handb Exp Pharmacol; 2019; 250():145-180. PubMed ID: 30838456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mirtazapine : A Review of its Pharmacology and Therapeutic Potential in the Management of Major Depression.
    Davis R; Wilde MI
    CNS Drugs; 1996 May; 5(5):389-402. PubMed ID: 26071050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of venlafaxine in rational antidepressant therapy.
    Feighner JP
    J Clin Psychiatry; 1994 Sep; 55 Suppl A():62-8; discussion 69-70, 98-100. PubMed ID: 7961545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venlafaxine: a structurally unique and novel antidepressant.
    Morton WA; Sonne SC; Verga MA
    Ann Pharmacother; 1995 Apr; 29(4):387-95. PubMed ID: 7633018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venlafaxine:a novel antidepressant compound.
    Schweizer E; Thielen RJ; Frazer A
    Expert Opin Investig Drugs; 1997 Jan; 6(1):65-78. PubMed ID: 15989562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venlafaxine: a heterocyclic antidepressant.
    Ellingrod VL; Perry PJ
    Am J Hosp Pharm; 1994 Dec; 51(24):3033-46. PubMed ID: 7856622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venlafaxine. A review of its pharmacology and therapeutic potential in depression.
    Holliday SM; Benfield P
    Drugs; 1995 Feb; 49(2):280-94. PubMed ID: 7729333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic options for treating major depression, and the role of venlafaxine.
    Scott MA; Shelton PS; Gattis W
    Pharmacotherapy; 1996; 16(3):352-65. PubMed ID: 8726593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurobiologic basis of antidepressant safety profiles.
    Hackett D; Salinas E
    Eur Psychiatry; 1997; 12 Suppl 4():301s-6s. PubMed ID: 19698584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacotherapeutic profile of venlafaxine.
    Preskorn S
    Eur Psychiatry; 1997; 12 Suppl 4():285s-94s. PubMed ID: 19698582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients.
    Nemeroff CB; Thase ME;
    J Psychiatr Res; 2007; 41(3-4):351-9. PubMed ID: 16165158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reboxetine, the first selective noradrenaline reuptake inhibitor antidepressant: Efficacy and tolerability in 2613 patients.
    Versiani M
    Int J Psychiatry Clin Pract; 2000; 4(3):201-8. PubMed ID: 24927454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerability and safety: essentials in antidepressant pharmacotherapy.
    Lader MH
    J Clin Psychiatry; 1996; 57 Suppl 2():39-44. PubMed ID: 8626362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid onset of action of venlafaxine.
    Montgomery SA
    Int Clin Psychopharmacol; 1995 Mar; 10 Suppl 2():21-7. PubMed ID: 7622814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review of duloxetine and venlafaxine in major depression, including unpublished data.
    Schueler YB; Koesters M; Wieseler B; Grouven U; Kromp M; Kerekes MF; Kreis J; Kaiser T; Becker T; Weinmann S
    Acta Psychiatr Scand; 2011 Apr; 123(4):247-65. PubMed ID: 20831742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression.
    Fawcett J; Barkin RL
    J Affect Disord; 1998 Dec; 51(3):267-85. PubMed ID: 10333982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SNRIs: mechanism of action and clinical features.
    Lambert O; Bourin M
    Expert Rev Neurother; 2002 Nov; 2(6):849-58. PubMed ID: 19810918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
    Davidson JR; Meoni P; Haudiquet V; Cantillon M; Hackett D
    Depress Anxiety; 2002; 16(1):4-13. PubMed ID: 12203668
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.